內視鏡止血設備市場:各市場區隔規模，佔有率，法律規章，償付，介入，2036年為止的預測

內視鏡止血裝置包括用於治療胃腸道 (GI) 出血的裝置，通常作為第一線治療。內視鏡止血裝置通常分為機械裝置（夾子、結紮器、縫線、支架）、注射裝置（注射針）、熱裝置（止血探針、止血鉗、加熱探針、氬氣凝固、射頻消融、冷凍療法）和局部裝置（止血噴霧劑）。

內視鏡止血技術是治療消化道出血的技術，作為首選治療方法。內視鏡止血的適應症包括各種上、下消化道出血疾病。上消化道出血主要包括消化性潰瘍出血、靜脈曲張出血，而憩室出血和良性肛門出血是下消化道出血住院最常見的原因。

本報告對全球內視鏡止血設備市場進行了詳細分析，提供了競爭格局、 SWOT 分析、 2036 年市場預測、區域和國家趨勢。

目錄

現在上市的內視鏡止血設備和競爭情形

• 主要的產業趨勢的洞察
• 內視鏡止血設備的各市場區隔整體市場收益和2015年～2036年的市場展望
• 各市場區隔的介入總數，台數，平均銷售價格，市場價值相關詳細資料

世界，地區，各國洞察

• 內視鏡止血設備市場SWOT分析
• 內視鏡止血設備市場相關競爭動態的洞察和趨勢
• 各國醫療制度概要
• 各國償付政策
• 各國醫療技術相關法規狀況

Endoscopic Hemostasis Devices Market Size by Segments, Share, Regulatory, Reimbursement, Interventions and Forecast to 2036 is built to visualize quantitative and qualitative market trends within Endoscopy Devices therapeutic area.

Endoscopic Hemostasis Devices consists of devices employed in the management of Gastrointestinal (GI) bleeding and often acts as the first line of therapy. Endoscopic Hemostasis Devices are generally classified into mechanical devices (clips, ligation devices, suturing devices, stents), injection devices (injection needles), thermal devices (hemostatic probes, hemostatic forceps, heater probe, argon plasma coagulation, radiofrequency ablation, and cryotherapy) and topical devices (hemostatic spray).

Endoscopic Hemostasis is a technique employed in the management of Gastrointestinal (GI) bleeding and often acts as the first line of therapy. The indications of endoscopic hemostasis technique include various upper and lower gastrointestinal bleeding diseases. Upper GI bleeding mainly includes peptic ulcer bleeding and variceal bleeding while diverticular bleeding and benign anorectal bleeding are the most common etiologies for hospital admissions with lower GI bleeding.

Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications with intervention volumes. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Endoscopic Hemostasis Devices and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Endoscopic Hemostasis Devices market revenue by segment and market outlooks from 2015-2036.
• Granular data on total Interventions, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Endoscopic Hemostasis Devices market.
• Competitive dynamics insights and trends provided for Endoscopic Hemostasis Devices market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Boston Scientific Corp, ConMed Corp, Wilson-Cook Medical Inc, ERBE Elektromedizin GmbH, Olympus Corp, United States Endoscopy Group Inc, Micro-Tech Nanjing Co Ltd, Integra LifeSciences Holdings Corp, Medline Industries LP, Diversatek Inc, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Endoscopic Hemostasis market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
• Develop business strategies by understanding the trends shaping and driving Endoscopic Hemostasis Devices market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Endoscopic Hemostasis Devices market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Endoscopic Hemostasis Devices market from 2015-2036.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.